Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;13(4):815-817.
doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.

A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)"

Sepideh Attal  1
Affiliations

A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)"

Sepideh Attal. Cardiol Ther. 2024 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Sepideh Attal is an employee of Pfizer and holds stock/stock options. Ethical Approval: This letter is based on a previously conducted study and does not contain any new studies with human participants or animals performed by the author.

Similar articles

See all similar articles

References

    1. Attal S, Kemner J, Alvir J, Barth S, Schuessler S. Tafamidis 61 mg patient characteristics and persistency? A retrospective analysis of German statutory health insurance data (IQVIA LRx). Cardiol Ther. 2024;13:369–78. 10.1007/s40119-024-00365-6. - PMC - PubMed
    1. Kristen AV, Tschope C, Schwarting S, Aus dem Siepen F. Letter to the editor regarding “Tafamidis 61 mg patient characteristics and persistency? A retrospective analysis of German statutory health insurance data (IQVIA™ LRx)”. Cardiol Ther. 2024. 10.1007/s40119-024-00382-5. - PMC - PubMed
    1. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512–26. 10.1002/ejhf.2140. - PubMed
    1. Tschope C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022;11:2148. 10.3390/jcm11082148. - PMC - PubMed
    1. Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: a systematic review and meta-analysis. Int J Cardiol. 2024;402: 131813. 10.1016/j.ijcard.2024.131813. - PubMed

LinkOut - more resources